LYEL insider transaction filings
Lyell Immunopharma, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-10. Screen LYEL transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 14 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 10 filings by 6 insiders — 13,786 shares, $211,301 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
- Largest priced transaction: sale of 9,589 shares @ $15.54 ($149,013) by Seely Lynn, filed 2026-08-25.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Seely Lynn — President and CEO, Director | 2 | — | 2 legs · 9,979 sh · $154,606 | — |
| Lee Gary K. — Chief Scientific Officer | 2 | — | 2 legs · 1,588 sh · $24,520 | — |
| Hill Stephen J. — Chief Operating Officer | 2 | — | 2 legs · 1,078 sh · $16,645 | — |
| Bulis Veronica Sanchez — VP, Corporate Controller | 1 | — | 1 leg · 621 sh · $8,905 | — |
| Shook David — Chief Medical Officer | 1 | — | 1 leg · 500 sh · $6,350 | — |
| Innovative Cellular Therapeutics Holdings Ltd — 10% owner | 5 | — | 2 legs · 20 sh · $274 | 3 |
| Aguirre Jarrad Mattieu — Chief Medical Officer | 1 | — | — | 1 |
Recent Form 4 filings — Lyell Immunopharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-10 | 4 | Shook David — Chief Medical Officer | Sale (S): 500 @ $12.70 | EDGAR |
| 2026-09-10 | 4 | Aguirre Jarrad Mattieu — Chief Medical Officer | Grant/award (A): 47,500 (derivative) @ $0 | EDGAR |
| 2026-08-25 | 4 | Lee Gary K. — Chief Scientific Officer | Sale (S): 1,457 @ $15.54 | EDGAR |
| 2026-08-25 | 4 | Hill Stephen J. — Chief Operating Officer | Sale (S): 989 @ $15.54 | EDGAR |
| 2026-08-25 | 4 | Seely Lynn — President and CEO, Director | Sale (S): 9,589 @ $15.54 | EDGAR |
| 2026-08-11 | 4 | Bulis Veronica Sanchez — VP, Corporate Controller | Sale (S): 621 @ $14.34 | EDGAR |
| 2026-08-11 | 4 | Lee Gary K. — Chief Scientific Officer | Sale (S): 131 @ $14.34 | EDGAR |
| 2026-08-11 | 4 | Hill Stephen J. — Chief Operating Officer | Sale (S): 89 @ $14.34 | EDGAR |
| 2026-08-11 | 4 | Seely Lynn — President and CEO, Director | Sale (S): 390 @ $14.34 | EDGAR |
| 2026-07-27 | 4 | Innovative Cellular Therapeutics Holdings Ltd — 10% owner | Other (J): 44,000 @ $0 | EDGAR |
| 2026-07-27 | 4 | Innovative Cellular Therapeutics Holdings Ltd — 10% owner | Other (J): 38,500 @ $0 | EDGAR |
| 2026-07-20 | 4 | Innovative Cellular Therapeutics Holdings Ltd — 10% owner | Sale (S): 10 @ $13.70 | EDGAR |
| 2026-07-17 | 4 | Innovative Cellular Therapeutics Holdings Ltd — 10% owner | Sale (S): 10 @ $13.73 | EDGAR |
| 2026-07-01 | 4 | Innovative Cellular Therapeutics Holdings Ltd — 10% owner | Other (J): 76,000 @ $0 | EDGAR |
| 2026-06-18 | 4 | Innovative Cellular Therapeutics Holdings Ltd — 10% owner | Other (J): 66,500 @ $0 | EDGAR |
| 2026-06-15 | 4 | Bulis Veronica Sanchez — VP, Corporate Controller | Sale (S): 217 @ $18.91 | EDGAR |
| 2026-06-15 | 4 | Lee Gary K. — Chief Scientific Officer | Sale (S): 130 @ $18.92 | EDGAR |
| 2026-06-15 | 4 | Hill Stephen J. — Chief Operating Officer | Sale (S): 89 @ $18.92 | EDGAR |
| 2026-06-15 | 4 | Seely Lynn — President and CEO, Director | Sale (S): 388 @ $18.91 | EDGAR |
| 2026-06-12 | 4 | Bachleda Mark — Director | Grant/award (A): 9,250 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | NABEL ELIZABETH G — Director | Grant/award (A): 9,250 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Klausner Richard — Director | Grant/award (A): 9,250 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Ramachandra Sumant — Director | Grant/award (A): 9,250 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | FRIEDMAN CATHY — Director | Grant/award (A): 9,250 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | BRAWLEY OTIS W — Director | Grant/award (A): 9,250 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | RIEFLIN WILLIAM JL — Director | Grant/award (A): 9,250 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Shook David — Chief Medical Officer | Sale (S): 1,977 @ $12.64 | EDGAR |
| 2026-03-16 | 4 | Shah Smital — Chief Fin. and Bus. Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | ARCH Venture Partners IX, LLC — 10% owner ARCH Venture Partners IX, L.P. — 10% owner ARCH Venture Partners IX Overage, L.P. — 10% owner ARCH Venture Fund IX, L.P. — 10% owner ARCH Venture Fund IX Overage, L.P. — 10% owner | Purchase (P): 488,090 @ $25.61 | EDGAR |
| 2026-03-09 | 4 | ARCH Venture Fund XIII, L.P. — 10% owner ARCH Venture Partners XIII, L.P. — 10% owner ARCH Venture Partners XIII, LLC — 10% owner CRANDELL KEITH — 10% owner NELSEN ROBERT — 10% owner Burow Kristina — 10% owner GILLIS STEVEN — 10% owner BERNS PAUL L — 10% owner BYBEE CLINTON — 10% owner | Purchase (P): 488,090 @ $25.61 | EDGAR |
| 2026-02-12 | 4 | Lee Gary K. — Chief Scientific Officer | Sale (S): 1,671 @ $23.39 | EDGAR |
| 2026-02-12 | 4 | Hill Stephen J. — Chief Operating Officer | Sale (S): 1,236 @ $23.39 | EDGAR |
| 2026-02-12 | 4 | Seely Lynn — President and CEO, Director | Sale (S): 7,455 @ $23.39 | EDGAR |
| 2026-02-11 | 4 | Bulis Veronica Sanchez — VP, Corporate Controller | Grant/award (A): 8,750 @ $0 · Sale (S): 254 @ $23.12 | EDGAR |
| 2026-02-11 | 4 | Shook David — Chief Medical Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Lee Gary K. — Chief Scientific Officer | Grant/award (A): 4,000 @ $0 · Sale (S): 147 @ $23.12 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Hill Stephen J. — Chief Operating Officer | Grant/award (A): 4,000 @ $0 · Sale (S): 109 @ $23.12 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Meltz Mark A — General Counsel | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Seely Lynn — President and CEO, Director | Grant/award (A): 20,000 @ $0 · Sale (S): 438 @ $23.12 · Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Bulis Veronica Sanchez — VP, Corporate Controller | Sale (S): 1,136 @ $38.67 · Sale (S): 936 @ $32.32 | EDGAR |
| 2025-11-12 | 4 | Bulis Veronica Sanchez — VP, Corporate Controller | Sale (S): 239 @ $16.10 | EDGAR |
| 2025-11-12 | 4 | Lee Gary K. — Chief Scientific Officer | Sale (S): 138 @ $16.16 | EDGAR |
| 2025-11-12 | 4 | Hill Stephen J. — Chief Operating Officer | Sale (S): 95 @ $16.12 | EDGAR |
| 2025-11-12 | 4 | Seely Lynn — President and CEO, Director | Sale (S): 412 @ $16.11 | EDGAR |
| 2025-10-29 | 4 | Lee Gary K. — Chief Scientific Officer | Grant/award (A): 68,000 (derivative) @ $0 | EDGAR |
| 2025-10-29 | 4 | Hill Stephen J. — Chief Operating Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-10-29 | 4 | Seely Lynn — President and CEO, Director | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2025-08-22 | 4 | Newton Charles W. — Chief Financial Officer | Grant/award (A): 8,000 @ $0 · Sale (S): 1,453 @ $10.54 | EDGAR |
| 2025-08-22 | 4 | Lee Gary K. — Chief Scientific Officer | Grant/award (A): 8,000 @ $0 · Sale (S): 1,453 @ $10.54 | EDGAR |
| 2025-08-22 | 4 | Seely Lynn — President and CEO, Director | Grant/award (A): 40,000 @ $0 · Sale (S): 7,257 @ $10.54 | EDGAR |
Recent 8-K events — Lyell Immunopharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-12-05 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LYEL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →